Summary.-A micro -cytotoxicity assay was adapted for the detection of cell-dependent antibodies (CDA). Using normal rat spleens as the source of effector cells such CDA activity was readily demonstrable in allo-immune sera tested on cultured sarcoma cells. The same technique was then used to examine for tumour specific antibodies in the sera of Hooded rats bearing a " non-immunogenic " syngeneic metastasizing sarcoma. During the early stages of tumour growth, at Days 7 and 14, tumour specific CDA cytotoxici1y was detectable at high titres. By Day 21, however, this activity had completely disappeared from the serum. This celldependent cytotoxicity was tumour specific in that it did not kill cells from an unrelated syngeneic sarcoma, and the activity was probably confined to immunoglobulin G as detected by molecular weight separation techniques. Following tumour amputation at Day 21, this type of specific antibody activity rapidly re-appeared in the serum. The presence of tumour specific CDA showed an inverse correlation with the presence of specific inhibitors of cell-mediated immunity in the same sera. At no stage in tumour growth could complement-dependent cytotoxicity be detected in tumour bearing rat sera.
RECENTLY the distinction between humoral and cellular effector mechanisms has become blurred. Non-immune lymphoid cells may be induced to lyse target cells in vitro by the addition of specific antibody (Moller, 1965) . This phenomenon of the cell dependence of antibody activity has been intensively investigated and reviewed by Perlmann, Perlmann and Wigzell (1972) and MacLennan (1972) . Cell-dependent antibody (CDA) activity has been detected in both xenogeneic and allogeneic antisera. Hersey and his colleagues (Hersey, Cullen and MacLennan, 1973) have demonstrated such CDA activity against HLA antigens in multiparous sera and have indicated that additional specificities, not detected by the conventional complement-dependent lytic assay, were revealed. Furthermore, CDA phenomena are frequently detectable at extremely low concentrations of antibody. Perlmann and his colleagues (Perlmann et al., 1972) using xenogeneic antisera against fowl erythrocytes have detected lytic effects at titres of 1 in 109 and have concluded that as few as 100 specific immunoglobulin molecules are sufficient to lyse an erythrocyte. The nature of the co-operating effector cells is as yet unclear; they are apparently plentiful in spleen, peritoneal exudate and blood, but absent from thoracic duct lymph. Earlier studies (MacLennan, 1972) have implied that the responsible cell is a lymphocyte and, as a result, the antibody effect has become known as lymphocyte-dependent antibody (LDA). Until the identity of this cell is established beyond dispute it would seem rational to employ the term "cell-dependent antibody" (CDA).
The exquisite economy in the use of antibody and the non-specific requirement for effector cells make this CDA phenomenon an attractive mechanism, potentially relevant in tumour specific reactions.
The studies of Lamon and his colleagues (Lamon et al., 1973) , which show that the effector cells in tumour bearing animals, capable of specifically lysing tumour cells were not T lymphocytes, could indicate a possible role for cellco-operating antibody. A form of serumcell co-operation has been described by Pollack and her colleagues (Pollack et al., 1972; Pollack, 1973) who showed that normal lymphoid cells can be rendered specifically cytotoxic by sera from mice bearing a syngeneic tumour, and recently Hellstrom, Hellstrom and Warner (1973) have described a similar specific " arming " of normal peripheral blood lymphoid cells by the sera from a few cancer patients. While these studies have revealed a serum factor which " arms " lymphoid cells they did not demonstrate either the presence of antibody or any affinity of the active component for tumour cells. Co-operation of tumour specific antibodies with non-sensitized cells may constitute a potent effector limb of the host's immune reactions to tumour cells.
This communication describes experiments designed to detect such celldependent tumour specific antibodies in rats bearing a syngeneic spontaneously metastasizing sarcoma, and to examine the influence of tumour growth and tumour amputation on such antibody activity.
MATERIALS AND METHODS
Rats. The animals used for these experiments were adult pure line Wistar and Hooded rats. Each strain is genetically and antigenically homogeneous as detected by skin grafting, maintained free of specific pathogens and the rats were used between 10 and 14 weeks of age.
Tumours.-The tumour used for these studies (MC3) has been described in a previous
paper (Currie and Gage, 1973 Target cells. Cells from both MC3 and HSN tumours were prepared and grown in RPMI 1.640 plus 10% foetal bovine serum and 10 mmol HEPES as previously described (Currie and Gage, 1973 83+7 2 l)oy 6 Post -"nep. Greenberg et al. (1973) . Studies of the presence, nature and evolution of effector cells in MC3 tumour bearing rats are in progress.
The mode of co-operation between cells and antibody which leads to target cell lysis is unknown. One could, of course, suggest that the effector cells are merely a source of complement produced locally at the site of antibody binding. However, the addition of carrageenan, a potent complement inhibitor to CDA lytic systems, does not inhibit cytotoxicity (Yust et al., 1973) . Furthermore, the addition of exogenous complement to our assays of tumour bearing sera evoked no detectable target cell lysis. The addition of the same complement source to an allogeneic antiserum assay led to lysis of MC3 and HSN target cells, although at titres substantially below those at which the CDA effect occurs with the same serum. It seems unlikely that such a complement effect can be incriminated in the CDA cytotoxicity.
With increasing tumour growth the CDA activity disappears from the serum, as do specifically cytotoxic cells in the regional lymph nodes in the same model system (Currie and Gage, 1973) . Following amputation of the tumour bearing limb at Day 21 the antibodies rapidly reappear in the circulation. This finding suggests that the presence of a large growing tumour in some way suppresses or absorbs out any circulating anti-TSTA antibodies. The studies of Thomson, Steele and Alexander (1973) rule out the latter, and suggest that the release of soluble cell-surface antigenic determinants by complexing with the antibodies may be responsible for clearing them from the circulation. This is further supported by our recent observation that the cells of the MC3 sarcoma when in tissue culture spontaneously shed soluble TSTA determinants at a high rate (Currie and Alexander, 1974) . Thus, the evolution of humoral immunity in the tumour bearing animal described above may well be related to the spontaneous shedding of soluble antigen. With increasing tumour growth the antibodies would eventually be overwhelmed until a condition of antigen excess occurs throughout the extracellular fluid. The gradual disappearance of circulating antibody leads to speculation about its possible in vivo significance. As suggested by the work of Proctor et al. (1973) circulating humoral factors may be responsible for the inhibition of pulmonary metastases. Currie and Sime (1973) have also shown that tumour specific antibodies inhibit the motility of tumour cells and suggested that they may consequently inhibit the in vivo dissemination of cells, thereby limiting invasiveness and metastases.
The unique properties of this mode of action of specific antibody which make it such an attractive concept are its requirement for unsensitized effector cells and its activity at very low concentrations. The presence of tumour specific antibodies which can co-operate with lymphoid cells to kill target tumour cells in the serum of tumour bearing animals would suggest that humoral mechanisms may play a role in host resistance to tumour growth. At present it is difficult to ascribe such an important role to this mechanism. As MacLennan (1972) has emphasized, celldependent antibody-mediated target cell destruction can be inhibited or blocked in many ways. Unrelated immune complexes, free antigen or even immunoglobulin all readily block CDA effects. Furthermore, the effector cells are absent from lymph and scarce in lymph nodes. Lymph nodes, of course, constitute an important site of host defence. The presence of effector cells in peripheral blood, spleen and peritoneal cavity could, nevertheless, provide a potent systemic effector mechanism in the peripheral extracellular fluid responsible for the inhibition of metastatic disease. The potential significance of CDA in tumour immunity and host resistance must remain a subject for speculation. This mode of action of anti-TSTA antibodies may, of course, represent an artificial in vitro effect with little direct relevance to the intact organism. Should this prove to be the case, however, it still represents an extremely potent assay system for the detection of anti-tumour antibodies.
